2. Search Result
Search Result
Results for "

edema inhibitor

" in MedChemExpress (MCE) Product Catalog:

174

Inhibitors & Agonists

4

Fluorescent Dyes

3

Biochemical Assay Reagents

4

Peptides

4

Inhibitory Antibodies

28

Natural
Products

11

Isotope-Labeled Compounds

1

GMP Molecules

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-W008574
    TGN-020
    20+ Cited Publications

    		 PROTAC Linkers Inflammation/Immunology Cancer
    TGN-020 is a selective Aquaporin 4 (AQP4) inhibitor with an IC50 of 3.1 μM . TGN-020 is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs .TGN-020 alleviates edema and inhibits glial scar formation after spinal cord compression injury in rats .
    TGN-020
  • HY-101872
    GSK-872
    Maximum Cited Publications
    100 Publications Verification

    		 RIP kinase Inflammation/Immunology
    GSK-872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury .
    GSK-872
  • HY-B0580
    Ketorolac
    3 Publications Verification

    RS37619

    		 COX Apoptosis Inflammation/Immunology Cancer
    Ketorolac (RS37619) is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorolac tromethamine is also a DDX3 inhibitor that can be used for cancer research .
    Ketorolac
  • HY-W008574A
    TGN-020 sodium
    20+ Cited Publications

    		 PROTAC Linkers Inflammation/Immunology Cancer
    TGN-020 sodium is a selective Aquaporin 4 (AQP4) inhibitor with an IC50 of 3.1 μM . TGN-020 sodium is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs . TGN-020 sodium alleviates edema and inhibits glial scar formation after spinal cord compression injury in rats .
    TGN-020 sodium
  • HY-101872A
    GSK-872 hydrochloride
    Maximum Cited Publications
    100 Publications Verification

    		 RIP kinase Inflammation/Immunology
    GSK-872 hydrochloride is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 hydrochloride decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury .
    GSK-872 hydrochloride
  • HY-N6028
    Darutoside
    1 Publications Verification

    		 COX NF-κB Interleukin Related TNF Receptor Inflammation/Immunology
    Darutoside is an orally effective diterpene compound with significant anti-inflammatory, analgesic, wound healing promotion, and immunomodulatory activities. Darutoside reduces edema and pain responses by inhibiting the expression of COX-2 and the migration of inflammatory cells. It regulates macrophage polarization towards the M2 type by inhibiting the NF-κB pathway, alleviating inflammation and promoting wound healing. Through multi-target regulation of metabolic networks, Darutoside significantly alleviates acute gouty arthritis .
    Darutoside
  • HY-109127
    Berotralstat
    1 Publications Verification

    BCX7353

    		 Kallikrein Cardiovascular Disease Cancer
    Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema .
    Berotralstat
  • HY-145633
    Sozinibercept

    OPT 302; VGX-300

    		 VEGFR Cardiovascular Disease
    Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .
    Sozinibercept
  • HY-B1363
    Bendroflumethiazide

    Bendrofluazide

    		 NKCC Cardiovascular Disease
    Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus .
    Bendroflumethiazide
  • HY-P0095
    Acetyl tetrapeptide-5

    		Angiotensin-converting Enzyme (ACE) Others
    Acetyl tetrapeptide-5 inhibits glycosylation and ACE-1 activity. Acetyl tetrapeptide-5 reduces edema and relieves vascular pressure by improving the vascular system and strengthening the skin under the eyes. Acetyl tetrapeptide-5 can be used in the research of Antioxidant, anti-aging skin care .
    Acetyl tetrapeptide-5
  • HY-N0924
    (±)-Stylopine
    1 Publications Verification

    Tetrahydrocoptisine

    		 Interleukin Related NO Synthase p38 MAPK PERK NF-κB Neurological Disease Inflammation/Immunology
    (±)-Stylopine (Tetrahydrocoptisine) is an alkaloid compound. (±)-Stylopine can be isolated from the tubers of the plant Corydalis. (±)-Stylopine inhibits TNF-α, IL-6, and NO production, and attenuates phosphorylation of p38 MAPK, ERK1/2. (±)-Stylopine inhibits NF-κB expression. (±)-Stylopine exhibits anti-inflammatory activity. (±)-Stylopine has protective effects against foot edema, gastric ulcers, anxiety, depression, and acute lung injury .
    (±)-Stylopine
  • HY-B0135A
    Furosemide sodium
    5+ Cited Publications

    		 NKCC GABA Receptor Cardiovascular Disease Metabolic Disease Cancer
    Furosemide sodium is a potent and orally active inhibitor of Na +/K +/2Cl - (NKCC) cotransporter, NKCC1 and NKCC2 . Furosemide sodium is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .
    Furosemide sodium
  • HY-48917
    C10 Bisphosphonate

    		Phospholipase Apoptosis Inflammation/Immunology
    C10 Bisphosphonate is an acid sphingomyelinase (aSMase) inhibitor with an IC50 of 0.02 μM in rats. C10 Bisphosphonate inhibits Dexamethasone (HY-14648)-induced cell apoptosis (apoptosis) and alleviates platelet-activating factor (PAF)-induced pulmonary edema. C10 Bisphosphonate can be used for the research of pulmonary edema .
    C10 Bisphosphonate
  • HY-W021267
    3-Demethylcolchicine

    		Reactive Oxygen Species (ROS) Inflammation/Immunology
    3-Demethylcolchicine, a colchicine metabolite and anti-inflammatory agent, exhibits potent tubulin-binding activity. 3-Demethylcolchicine inhibits carrageenan-induced rat paw edema. 3-Demethylcolchicine bears a hydroxyl group on its carbocyclic ring; this group participates in free radical scavenging processes, allowing it to act as a free radical scavenger. 3-Demethylcolchicine is applicable to studies related to carrageenan-induced paw edema .
    3-Demethylcolchicine
  • HY-N2556
    Tirucallol

    		Others Inflammation/Immunology
    Tirucallol, a tetracyclic triterpene, is isolated from Euphorbia lacteal latex. Tirucallol has topical anti-inflammatory effect. Tirucallol can suppress ear edema in the mouse model and inhibit nitrite production in lipopolysaccharide-stimulated macrophages .
    Tirucallol
  • HY-133712
    Yonkenafil

    Tunodafil

    		 Phosphodiesterase (PDE) Neurological Disease
    Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease .
    Yonkenafil
  • HY-136642
    Fluocinolone

    		Glucocorticoid Receptor Inflammation/Immunology
    Fluocinolone is a potent steroid with highly selective glucocorticoid receptor agonist activity. Fluocinolone stabilizes the blood-retinal barrier by enhancing endothelial tight junctions, inhibiting the VEGF pathway and inflammatory factors. Fluocinolone has high lipophilicity, enabling long-term sustained release in the vitreous. Fluocinolone is used in research related to dermatological diseases, diabetic macular edema, uveitis and oral lichen planus .
    Fluocinolone
  • HY-109127A
    Berotralstat dihydrochloride
    1 Publications Verification

    BCX7353 dihydrochloride

    		 Kallikrein Cardiovascular Disease Cancer
    Berotralstat dihydrochloride (BCX7353 dihydrochloride) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema .
    Berotralstat dihydrochloride
  • HY-W013164
    SC-58125

    		COX Inflammation/Immunology Cancer
    SC-58125 is a potent and selective inhibitor of cyclooxygenase 2 (COX-2), with an IC50 of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo. SC-58125 also can inhibit edema at the inflammatory site and has analgesic effect .
    SC-58125
  • HY-N10341
    Centaureidin

    		IFNAR ROCK Inflammation/Immunology Cancer
    Centaureidin is an orally active IFN-promoter that can be isolated from Bidens pilosa with an EC50 of 0.9 μg/mL. Centaureidin activates the Rho signal pathway, leading to actin and tubulin disassembly, and resulting in dendrite retraction and stress fiber formation in melanocytes. Centaureidin shows high tumor cell growth inhibitory activities. Centaureidin significantly inhibits paw edema in mice [1][2][3][4][5].
    Centaureidin
  • HY-B1640R
    Ethacrynic acid (Standard)
    5+ Cited Publications

    Etacrynic acid (Standard)

    		 Reference Standards Glutathione S-transferase NF-κB Calcium Channel Inflammation/Immunology Cancer
    Ethacrynic acid (Standard) is the analytical standard of Ethacrynic acid. This product is intended for research and analytical applications. Ethacrynic acid (Etacrynic acid) is a diuretic. Ethacrynic acid is an inhibitor of glutathione S-transferases (GSTs). Ethacrynic acid is a potent inhibitor of NF-kB-signaling pathway, and also modulates leukotriene formation. Ethacrynic acid also inhibits L-type voltage-dependent and store-operated calcium channel, leading to relaxation of airway smooth muscle (ASM) cells. Ethacrynic acid has anti-inflammatory properties that reduces the retinoid-induced ear edema in mice .
    Ethacrynic acid (Standard)
  • HY-N11072
    Tremulacin

    		Lipoxygenase Leukotriene Receptor Reactive Oxygen Species (ROS) MMP Inflammation/Immunology
    Tremulacin is a 5-LOX inhibitor. Tremulacin reduces the biosynthesis of LTB4 and slow-reacting substances of anaphylaxis. Tremulacin alleviates carrageenan-induced paw edema in rats, croton oil-induced ear edema in mice, and acetic acid-induced writhing response in mice. Tremulacin inhibits TNF-α-stimulated ROS production and MMP-1 expression, and promotes collagen secretion in human dermal fibroblasts. Tremulacin is investigated for studies on inflammation-related diseases .
    Tremulacin
  • HY-176464
    GSK2220691

    		TRP Channel Inflammation/Immunology
    SK2220691 is a potent TRPV4 inhibitor. SK2220691 inhibits pulmonary edema induced by GSK1016790. SK2220691 inhibits HCl-induced increases in key factors such as VEGF, keratinocyte-derived chemokine (KC; CXCL1), and granulocyte colony-stimulating factor (GCSF) .
    GSK2220691
  • HY-127072
    Amicoumacin A

    		Antibiotic Bacterial Infection Inflammation/Immunology Cancer
    Amicoumacin A is an orally active antibiotic. Amicoumacin A targets bacterial ribosomes and inhibits bacterial translation by stabilizing the interaction between mRNA and ribosomes. Amicoumacin A induces cancer cell death by targeting eukaryotic ribosomes. Amicoumacin A exhibits anti-inflammatory and anti-ulcer activities, inhibits carrageenan-induced paw edema, and prevents stress-induced gastric ulcers. Amicoumacin A inhibits the growth of Gram-positive bacteria, Salmonella spp., Shigella spp., Helicobacter pylori, and methicillin-resistant Staphylococcus aureus. Amicoumacin A can be used in the research of lung cancer, breast cancer, bacterial infections, inflammatory edema and gastric ulcers [2] .
    Amicoumacin A
  • HY-116763
    COX-2/5-LOX-IN-4

    		COX LOX-1
    COX-2/5-LOX-IN-4 (Compound 1) is a dual inhibitor that acts on both COX-2 and 5-LOX, with IC50 values of 0.05 μM for COX-2 and 0.003 μM for 5-LOX. By inhibiting the arachidonic acid metabolism pathway, COX-2/5-LOX-IN-4 reduces the production of prostaglandins and leukotrienes, alleviating inflammatory responses. In a rat ear edema model, intravenous administration (0.01 and 0.1 mg/kg) reduced edema by 41% and 44%, respectively, demonstrating significant anti-inflammatory effects. COX-2/5-LOX-IN-4 shows promise for studying the mechanisms of inflammatory diseases .
    COX-2/5-LOX-IN-4
  • HY-B1363S
    Bendroflumethiazide-d5

    Bendrofluazide-d5

    		 Isotope-Labeled Compounds NKCC Cardiovascular Disease
    Bendroflumethiazide-d5 (Bendrofluazide-d5) is the deuterium labeled Bendroflumethiazide (HY-B1363).Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus .
    Bendroflumethiazide-d5
  • HY-B1363R
    Bendroflumethiazide (Standard)

    Bendrofluazide (Standard)

    		 NKCC Reference Standards Cardiovascular Disease
    Bendroflumethiazide (Standard) (Bendrofluazide (Standard)) is the analytical standard of Bendroflumethiazide (HY-B1363). This product is intended for research and analytical applications. Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus .
    Bendroflumethiazide (Standard)
  • HY-W662576
    KVD-001

    		Kallikrein Cardiovascular Disease Metabolic Disease Endocrinology
    KVD-001 is a potent plasma kallikrein inhibitor. KVD-001 can be used for diabetic macular edema research .
    KVD-001
  • HY-150052
    Plasma kallikrein-IN-3

    		Kallikrein Cardiovascular Disease Metabolic Disease
    Plasma kallikrein-IN-3 is a plasma kallikrein inhibitor (IC50: 0.15 μM). Plasma kallikrein-IN-3 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research .
    Plasma kallikrein-IN-3
  • HY-19604
    SQ 26490

    		Glucocorticoid Receptor Inflammation/Immunology
    SQ 26490 is an active corticoid, moderate-potency edema formation inhibitor. SQ 26490 inhibits edema formation in rats .
    SQ 26490
  • HY-157226
    ORI-TRN-002

    		Aquaporin Others
    ORI-TRN-002 is an AQP4 inhibitor with an IC50 value of 3μM. ORI-TRN-002 can be used in the research area of cerebral edema .
    ORI-TRN-002
  • HY-150550
    COX-2-IN-26

    		COX Inflammation/Immunology
    COX-2-IN-26 is a potent, selective and orally active COX-2 inhibitor with IC50 values of 10.61, 0.067, 1.96 µM for COX-1, COX-2, 15-LOX, respectively. COX-2-IN-26 shows anti-inflammatory activity. COX-2-IN-26 shows gastrointestinal safety profile .
    COX-2-IN-26
  • HY-19295
    TRK-530 sodium

    		CXCR Inflammation/Immunology Endocrinology
    TRK-530 sodium is an orally active bisphosphonate. TRK-530 sodium inhibits CINC-1. TRK-530 sodium inhibits dental calculus formation. TRK-530 sodium also inhibits paw edema, joint destruction and osteomyelitis .
    TRK-530 sodium
  • HY-118725
    Luffariellolide

    		Phospholipase Inflammation/Immunology
    Luffariellolide is an inhibitor of human synovial fluid phospholipase A2 (HSF-PLA2) (IC50=5 μM). Luffariellolide effectively inhibits phorbol ester (PMA)-induced ear edema (ED50=50 μg/ear) .
    Luffariellolide
  • HY-143476
    Plasma kallikrein-IN-2

    		Kallikrein Cardiovascular Disease Metabolic Disease
    Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC50 of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research .
    Plasma kallikrein-IN-2
  • HY-W013164R
    SC-58125 (Standard)

    		Reference Standards COX Inflammation/Immunology Cancer
    SC-58125 is a potent and selective inhibitor of cyclooxygenase 2 (COX-2), with an IC50 of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo. SC-58125 also can inhibit edema at the inflammatory site and has analgesic effect .
    SC-58125 (Standard)
  • HY-134521
    Diclofenac amide

    		COX Inflammation/Immunology
    Diclofenac amide is a prodrug for Diclofenac sodium (HY-15037). Diclofenac amide is an orally active inhibitor for COX-1/2, that inhibits the production of prostaglandins (PG) and thromboxanes (TX). Diclofenac amide exhibits anti-inflammatory efficacy in Carrageenan (HY-125474)-induced rat paw edema model without causing gastric ulcer (300 μmol/kg) .
    Diclofenac amide
  • HY-14343
    KLYP961

    		NO Synthase Neurological Disease
    KLYP961 is a selective and orally active dual inhibitor of inducible and neuronal NO synthase (IC50 = 50-400 nM). KLYP961 can inhibit endotoxin-evoked plasma nitrates increases and attenuate pain behaviors in a mouse formalin model. KLYP961 can attenuate carrageenin-induced edema and inflammatory hyperalgesia and writhing response elicited by Phenylbenzoquinone (HY-W275039). KLYP961 can be used for the research of neurological disease .
    KLYP961
  • HY-15131
    PNRI-299

    		Interleukin Related Inflammation/Immunology
    PNRI-299 is a selective AP-1 transcription inhibitor with an IC50 of 20 uM. PNRI-299 is a selective APE/Ref-1 inhibitor. PNRI-299 has no effect on NF-κB transcription or thioredoxin (up to 200 uM). PNRI-299 significantly reduces airway eosinophil infiltration, mucus hypersecretion, edema, and IL-4 levels in a mouse asthma model .
    PNRI-299
  • HY-107592
    ACHP

    		IKK STAT Apoptosis Inflammation/Immunology Cancer
    ACHP (compound 4j) is a selective and orally active IκB kinase inhibitor with IC50 values of 8.5 nM and 250 nM for IKKβ and IKKα, respectively. ACHP can effectively inhibit the STAT3 signaling pathway and induce cancer cell cycle arrest and apoptosis. ACHP shows anti-inflammatory activity in a mouse ear edema model. ACHP can be used in anti-inflammatory and anti-cancer (such as multiple myeloma and leukemia) studies .
    ACHP
  • HY-175521
    HIF-1α-IN-8

    		HIF/HIF Prolyl-Hydroxylase IKK NF-κB Apoptosis Reactive Oxygen Species (ROS) Inflammation/Immunology
    HIF-1α-IN-8 is an orally active HIF-1α inhibitor, with an IC50 of 2.02 μM. HIF-1α-IN-8 significantly suppresses the expression of inflammation factors of IL-6 and NO, reduces hypoxia-induced ROS production and apoptosis in C8-D1A cells. HIF-1α-IN-8 inhibits HIF-1α/IKKα/NF-κB signaling pathway and reduces the expression of blood-brain barrier permeability-related proteins. HIF-1α-IN-8 reduces brain water content and oxidative stress level in mice with high altitude cerebral edema (HACE) model. HIF-1α-IN-8 can be used for the study of high altitude cerebral edema (HACE) .
    HIF-1α-IN-8
  • HY-119298
    AW-814141

    		p38 MAPK Inflammation/Immunology
    AW-814141 is a selective and orally active p38 MAP kinase inhibitor. AW-814141 has an IC50 values of 100 nM and 158 nM for p38-α and β isoforms, respectively. AW-814141 can inhibit the production of TNF-α induced by LPS (HY-D1056). AW-814141 can inhibit paw edema in rats in a dose-dependent manner. AW-814141 exhibits anti-inflammatory activity and can be used in the research of inflammatory diseases such as rheumatoid arthritis .
    AW-814141
  • HY-N1143
    Tomentin

    		Others Inflammation/Immunology
    Tomentin is a compound isolated from Sphaeralcea angustifolia. Tomentin inhibits the formation of λ-carrageenan footpad edema at 58 %. Tomentin inhibits the phorbol ester-induced auricular edema formation by 57 % .
    Tomentin
  • HY-150551
    COX-2-IN-27

    		COX Inflammation/Immunology
    COX-2-IN-27 is a potent and selective COX-2 inhibitor with IC50 values of 13.22, 0.045, 1.67 µM for COX-1, COX-2, 15-LOX, respectively. COX-2-IN-27 shows anti-inflammatory activity .
    COX-2-IN-27
  • HY-19646
    Zoliprofen

    480156-S

    		 Bradykinin Receptor Prostaglandin Receptor Neurological Disease
    Zoliprofen (480156-S), a new non-steroidal anti-inflammatory agent, has potent pain suppressing effect. Zoliprofen has strong antagonistic action against bradykinin, markedly inhibiting all bradykinin-induced edema and pain reactions. Zoliprofen weakly inhibits Arachidonic acid (HY-109590)-induced edema and pain reactions but also inhibits PGE2 synthesis of bovine vesicular gland microsomes .
    Zoliprofen
  • HY-126038
    BTS 39542

    		Chloride Channel Potassium Channel Sodium Channel Cardiovascular Disease
    BTS 39542 is an orally active inhibitor for Na+ K+ Cl cotransport system, that exhibits diuretic activity, and can be used in hypertension and edema research .
    BTS 39542
  • HY-108308
    Ibuprofen guaiacol ester

    Methoxybutropate; AF 2259; Metoxibutropate

    		 Prostaglandin Receptor Metabolic Disease Inflammation/Immunology
    Ibuprofen guaiacol ester (AF 2259; Metoxibutropate) is a potent and orally active prostaglandin synthesis inhibitor. Ibuprofen guaiacol ester has the potential for the research of edema and fever .
    Ibuprofen guaiacol ester
  • HY-100174
    W-2429

    NSC294836

    		 Others Neurological Disease
    W-2429 (NSC294836) is considerably more effective than acetylsalicylic acid in inhibiting carrageenan-induced edema and in reducing brewer's yeast-induced fever in rats .
    W-2429
  • HY-116873
    Flunoxaprofen

    		COX Inflammation/Immunology
    Flunoxaprofen is an orally active COX inhibitor. Flunoxaprofen shows anti-inflammatory activity in a rat paw edema model. Flunoxaprofen may be used in research on immune system diseases such as arthritis .
    Flunoxaprofen
  • HY-B2081
    Etozolin

    W-2900A

    		 Others Cardiovascular Disease Metabolic Disease
    Etozolin (W-2900A) is a diuretic agent. Etozolin inhibits fluid and electrolyte reabsorption in the loop of Henle. Etozolin can be used in research of congestive heart failure, hypertension and edema .
    Etozolin

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: